CGM's Impact on Clinical Inertia

Author(s):

Davida Kruger, MSN, APN-BC, BC-ADM ,Jaime Murillo, MD, FACC, FASE

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and supports earlier therapeutic interventions across different patient populations, highlighting measurable improvements in patient outcomes, such as glycemic control, hemoglobin A1c (HbA1c) levels, hypoglycemic events, and quality of life.

EP: 1.CGM: Redefining Type 2 Diabetes Management

EP: 2.Key Benefits of CGM Technology

Now Viewing

EP: 3.CGM's Impact on Clinical Inertia

Video content above is prompted by the following:

How does CGM adoption impact clinical inertia and support earlier therapeutic interventions across different patient populations?
What measurable improvements have been seen with CGMs in patient outcomes (eg, glycemic control, HbA_1c levels, hypoglycemic events, quality of life)?
Because each segment is considered a separate entity, each group of discussion questions should reset with No. 1 if using numbers.